The promise of therapeutics from molecules within our body
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
List view / Grid view
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
Heightened insulin resistance in obese men may elucidate the higher prevalence of type 2 diabetes among these individuals.
The discovery that omental fat has a mechanism to limit adipocyte formation may lead to new treatments for obesity and metabolic disease.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
New findings show that age-related MC4R+ cilia shortening causes middle-aged obesity and leptin resistance, which could lead to obesity treatment.
Researchers found that resolvinT4 restores protective macrophage biological activities in rheumatoid arthritis patients.
Excessive insulin levels in people with obesity and type 2 diabetes overstimulates pancreatic cells, initiating disease.
New Study from King's College London: Irregular Sleep Patterns Tied to Harmful Gut Bacteria.
The University of California underwent a mouse study disclosing underlying sex differences in mice for obesity.
Findings from the Republic of Ireland, in relation to GLP-1 obesity treatment showcase its ability to restore the body’s natural cancer-killing defences.
US researchers discover compound that limits weight gain in mice with a high-sugar diet, by lowering the mitochondrial magnesium.
Japanese researchers discover the mechanism of inhibition of diet-induced obesity in mice by the glucose-dependent insulinotropic polypeptide
The researchers found that the protein Grb10 promotes leptin activity in the brain, opening the possibility of developing Grb10-based new approaches to treat obesity.
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.